This publication by our Reasearch team at Ophthalmos shows that dietary supplementation with omega 3 can halt and reverse the retinal damage seen in Diabetic Retinopathy Link : https://www.imrpress.com/journal/FBL/28/7/10.31083/j.fbl2807153/htm
These findings by Ophthalmos Research team support the use of omega-3 polyunsaturated fatty acids as a therapy for autosomal dominant optic atrophy. Omega-3 fatty acid supplementation has neuroprotective effects on the retinas of a mouse model of OPA1-related autosomal dominant optic atrophy by blocking the inflammatory activation of astrocytes and microglia and by suppressing the …
The published paper by Ophthalmos Research team suggest that ω3 supplementation can be considered a therapeutic intervention against age-associated retinal dysfunction. The prevention of age-related loss of vision or enhancement of visual acuity in the elderly can significantly improve their quality of life, in addition to improving their function in activities of daily living.
Ophthalmos Research team has discovered a novel therapy for vision improvement in patients with Stargardt disease. It is one of the most common forms of macular dystrophy and to date no treatment has provided evidence of disease regression. The published paper shows how fatty acids reduced the accumulation of lipofuscin granules and A2E levels and …
The Research team at Ophthalmos Institute has confirmed that Omega-3 fatty acids can protect the optic nerve in glaucoma. ‘Glaucoma is the second leading cause of irreversible blindness, and affects 80 million people worldwide. Several risk factors, especially age and elevated intraocular pressure, play crucial roles in glaucoma development . However, the exact relationship between …
Ophthalmos Research Team have demonstrated that omega 3 fatty acids when used at the right dosage (by testing the blood AA/EPA ratio) could be beneficial in patients with Age Related Macular Degeneration and perhaps other ocular pathologies which involve photoreceptor damage. The benefits will have a positive impact on the quality of life of patients …
Ophthalmos Research team in collaboration with the research team of Professor Tsai from Tzui Chi University, Taiwan have demonstrated for the first time that omega 3 polyunsaturated fatty acids have neuroprotective effects on ischemic optic neuropathies. ‘This is of clinical significance as there is no treatment for ischemic optic neuropathies’ said Dr Tassos Georgiou the …
Age related Macular Degeneration is the leading cause of blindness over the age of 40 years old and Mauclar Dystrophy is the leading cause of blindness under the age of 40 years old.Ophthalmos publishes the results of its patented treatment to alleviate blindness See link: https://www.ncbi.nlm.nih.gov/pubmed/27125064
Ophthalmos has a patented therapy of moderate to severe dry eyes using omega 3 therapy. ‘Omega 3 is beneficial for dry eyes when given at the correct dose and ratio of EPA to DHA. This is simply decided by using a blood test to measure the ratio of AA to EPA’ said Dr Tassos Georgiou, …
AMD is the leading cause of visual impairment and blindness in people over the age of 50 years. The number of people with this disease is estimated at 200 million worldwide and this number is expected to increase in 20 years by 50 %.. In 2010 there was a direct healthcare systems expenditure of $255 …
